Identification of the SARS-unique domain of SARS-CoV-2 as an antiviral target
© 2023. The Author(s)..
SARS-CoV-2 nsp3 is essential for viral replication and host responses. The SARS-unique domain (SUD) of nsp3 exerts its function through binding to viral and host proteins and RNAs. Herein, we show that SARS-CoV-2 SUD is highly flexible in solution. The intramolecular disulfide bond of SARS-CoV SUD is absent in SARS-CoV-2 SUD. Incorporating this bond in SARS-CoV-2 SUD allowed crystal structure determination to 1.35 Å resolution. However, introducing this bond in SARS-CoV-2 genome was lethal for the virus. Using biolayer interferometry, we screened compounds directly binding to SARS-CoV-2 SUD and identified theaflavin 3,3'-digallate (TF3) as a potent binder, Kd 2.8 µM. TF3 disrupted the SUD-guanine quadruplex interactions and exhibited anti-SARS-CoV-2 activity in Vero E6-TMPRSS2 cells with an EC50 of 5.9 µM and CC50 of 98.5 µM. In this work, we provide evidence that SARS-CoV-2 SUD harbors druggable sites for antiviral development.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Nature communications - 14(2023), 1 vom: 06. Juli, Seite 3999 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Qin, Bo [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antiviral Agents |
---|
Anmerkungen: |
Date Completed 10.07.2023 Date Revised 18.11.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41467-023-39709-6 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM359158617 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM359158617 | ||
003 | DE-627 | ||
005 | 20231226080300.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41467-023-39709-6 |2 doi | |
028 | 5 | 2 | |a pubmed24n1197.xml |
035 | |a (DE-627)NLM359158617 | ||
035 | |a (NLM)37414753 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Qin, Bo |e verfasserin |4 aut | |
245 | 1 | 0 | |a Identification of the SARS-unique domain of SARS-CoV-2 as an antiviral target |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 10.07.2023 | ||
500 | |a Date Revised 18.11.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. The Author(s). | ||
520 | |a SARS-CoV-2 nsp3 is essential for viral replication and host responses. The SARS-unique domain (SUD) of nsp3 exerts its function through binding to viral and host proteins and RNAs. Herein, we show that SARS-CoV-2 SUD is highly flexible in solution. The intramolecular disulfide bond of SARS-CoV SUD is absent in SARS-CoV-2 SUD. Incorporating this bond in SARS-CoV-2 SUD allowed crystal structure determination to 1.35 Å resolution. However, introducing this bond in SARS-CoV-2 genome was lethal for the virus. Using biolayer interferometry, we screened compounds directly binding to SARS-CoV-2 SUD and identified theaflavin 3,3'-digallate (TF3) as a potent binder, Kd 2.8 µM. TF3 disrupted the SUD-guanine quadruplex interactions and exhibited anti-SARS-CoV-2 activity in Vero E6-TMPRSS2 cells with an EC50 of 5.9 µM and CC50 of 98.5 µM. In this work, we provide evidence that SARS-CoV-2 SUD harbors druggable sites for antiviral development | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Antiviral Agents |2 NLM | |
700 | 1 | |a Li, Ziheng |e verfasserin |4 aut | |
700 | 1 | |a Tang, Kaiming |e verfasserin |4 aut | |
700 | 1 | |a Wang, Tongyun |e verfasserin |4 aut | |
700 | 1 | |a Xie, Yubin |e verfasserin |4 aut | |
700 | 1 | |a Aumonier, Sylvain |e verfasserin |4 aut | |
700 | 1 | |a Wang, Meitian |e verfasserin |4 aut | |
700 | 1 | |a Yuan, Shuofeng |e verfasserin |4 aut | |
700 | 1 | |a Cui, Sheng |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 14(2023), 1 vom: 06. Juli, Seite 3999 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:06 |g month:07 |g pages:3999 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-023-39709-6 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2023 |e 1 |b 06 |c 07 |h 3999 |